A team with the participation of researchers from the ICMAB has designed new hydrogels for culturing T-cells or T-lymphocytes, cells of the immune system that are used in cancer immunotherapy with the capacity to destroy tumor cells. These hydrogels can…
Read More
Infection risk up in month after CAR T-cell immunotherapy
(HealthDay)—For children and young adults receiving CD19 chimeric antigen receptor (CAR) T-cell infusion (CTI), infection rates increase in the first month after treatment and then decrease, according to a study published in the May issue of Open Forum Infectious Diseases….
Read More
New cancer immunotherapy targeting myeloid cells slows tumor growth
Checkpoint inhibitors, a type of immunotherapy, that target myeloid immune cells and slow tumor growth were discovered by a team from the Perelman School of Medicine at the University of Pennsylvania and other institutions. Reporting in Nature Cancer, the researchers…
Read More
Clinically applicable math model predicts patient outcomes to cancer immunotherapy
Source: Read Full Article
Read More
Researchers investigate how cancer treatment could help with COVID-19 cure
These receptors are often used in cancer immunotherapy. In cancer immunotherapy the cells are engineered to intercept cancer cells and destroy them. In the case or coronavirus, the receptors would be modified to recognise the virus so it can kill off…
Read More
Immunotherapy combo achieves reservoir shrinkage in HIV model
Stimulating immune cells with two cancer immunotherapies together can shrink the size of the viral “reservoir” in SIV-infected non-human primates treated with antiviral drugs, researchers have concluded. The reservoir includes immune cells that harbor virus despite potent antiviral drug treatment….
Read More
Blood test can predict clinical response to immunotherapy in metastatic NSCLC
Non-small cell lung cancer (NSCLC) patients with higher measures of tumor mutations that show up in a blood test generally have a better clinical response to PD-1-based immunotherapy treatments than patients with a lower measure of mutations. A clinical trial…
Read More